<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185053</url>
  </required_header>
  <id_info>
    <org_study_id>CPC-001-07</org_study_id>
    <nct_id>NCT02185053</nct_id>
  </id_info>
  <brief_title>A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia</brief_title>
  <official_title>A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chase Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chase Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple
      Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with
      Alzheimer's Disease Type Dementia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Donepezil Maximum tolerated dose (MTD) change</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CPC-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPC-201</intervention_name>
    <arm_group_label>CPC-201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 50 - 79 years inclusive.

          -  Meeting the diagnosis of probable Alzheimer's Disease

          -  Of moderate severity (Mini-Mental Status Exam [MMSE] score 10 - 20 inclusive).

          -  Patients must be in generally good health as indicated by their medical history and
             physical examination, vital signs, electrocardiogram (ECG), and standard laboratory
             tests.

        Exclusion Criteria:

          -  Women of child bearing potential.

          -  History or presence of a seizure disorder.

          -  History of peptic ulcer disease, urinary or gastric retention; asthma or obstructive
             pulmonary disease.

          -  History or presence of bladder outflow obstruction, gastrointestinal obstructive
             disorder or reduced GI motility, or narrow-angle glaucoma.

          -  History or presence of gastrointestinal, hepatic, or renal disease, or other condition
             known to interfere with the absorption, distribution, metabolism or excretion of
             drugs.

          -  History or presence of myasthenia.

          -  Known hypersensitivity to donepezil, solifenacin or related drugs.

          -  Any other clinically relevant acute or chronic diseases which could interfere with
             patients' safety during the trial, or expose them to undue risk, or which could
             interfere with study objectives.

          -  Patients who have participated in another clinical trial with an investigational drug
             within previous 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CPC1</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

